Stores will remain open for now, but the company isnt buying new inventory so bare shelves are likely become more common
Combination therapies: Manufacturing companies and research organizations are heavily investing in research activities for developing combination therapies such as insulin with GLP-1 RA which can help in improving glycemic control, weight control and also for potential cardiovascular and kidney benefits further providing an individualized approach for patient treatment
Patients with a history of pancreatitis, severe gastrointestinal disease, or thyroid cancer are typically not candidates
Liraglutide (Victoza), injectable semaglutide (Ozempic), and dulaglutide (Trulicity) have demonstrated statistically significant reductions in major adverse cardiovascular events in clinical trials
Of note, metformin and a DPP-4 inhibitor additively increase active GLP-1 levels in the plasma [32], which confers clinical benefits in the management of type 2 diabetes